The deal builds on an existing research collaboration between Eli Lilly and Alchemab to discover new ALS drugs.

The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...

Eli Lilly (LLY) inks a licensing agreement with Alchemab to jointly develop an ALS drug in a $415M deal. Read more here.

Alchemab Therapeutics, a next-gen biopharmaceutical company, has entered into a licensing agreement with Eli Lilly and ...

Under terms of the deal, Alchemab will lead early Phase I trials for ATLX-1282 in amyotrophic lateral sclerosis, while Lilly ...

Financial terms of the new agreement include an upfront payment to secure rights to Alchemab's lead ALS candidate, ATLX-1282, ...

Alchemab Therapeutics, whose labs are in Cambridge UK, stands to scoop $415 million from Eli Lilly and Company following a ...

Alchemab Therapeutics has entered into a licensing agreement with Eli Lilly and Company (Lilly) for ATLX-1282, Alchemab’s ...

Just four months after Eli Lilly and British biotech Alchemab penned a discovery collaboration, the Big Pharma is licensing ...

Alchemab Therapeutics (Alchemab), the next generation biopharmaceutical company which uses the power of human immune evolution to identify and develop naturally occurring therapeutic antibodies from ...

Eli Lilly will be licensing Alchemab Therapeutics’ preclinical programme for amyotrophic lateral sclerosis (ALS) and other ...

Lilly licenses Alchemab’s ALS antibody ATLX-1282 in $415mn deal, expanding its neuroscience pipeline with a novel, ...